Evaluation of the immunohistochemical stain patterns of survivin, Bak and Bag-1 in colorectal cancers and comparison with polyps situated in the colon.
OBJECTIVE
Colorectal cancer is one of the most common cancers worldwide. The adenoma-carcinoma sequence in colorectal cancer has been documented approximately; however, several series of molecular mechanisms still require elucidation.


METHODS
Fifteen colonoscopic biopsy and 25 colectomy colorectal cancer samples, 12 hyperplastic colon polyps, and 18 tubular and 19 villous adenoma cases were studied. Apoptotic markers, such as Bag-1, survivin, and Bak, were used for staining, and relationships between stain features, clinical and prognostic factors, and polyp and tumor staining features were examined.


RESULTS
Significantly different staining patterns were observed between polyps and carcinomas. In tumor cells cytoplasmic Bag-1 expression was increased. As tumor differentiation degree tumor decreased, supranuclear granular staining features of Bcl-xl and Bak disappeared at a higher rate. With Bak, decrease of supranuclear granular staining was also related to vessel and nerve invasion, and tumor location. Survivin was expressed mostly in tumor cells, and sites with high inflammatory infiltration and vessel proliferation, where vessel endothelia were selectively stained.


CONCLUSIONS
Cytoplasmic staining of Bag-1 can be considered an indicator of tumor progression. Decrease of supranuclear granular staining with Bak and Bcl-xl, and survivin expression, can be used as indicators of poor prognosis. Survivin expression can also be used as a vessel marker.
Alper
Murat
M
Dişkapi Hospital, Pathology Department, Ankara, Turkey
Cukur
Selma
S
Belenli
Olcay
O
Suna
Mazlume
M
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003110:Colonic Neoplasms / Q000378:metabolism* / Q000473:pathology; D003111:Colonic Polyps / Q000378:metabolism* / Q000473:pathology; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000378:metabolism*; D000077022:Survivin; D014157:Transcription Factors / Q000378:metabolism*; D050998:bcl-2 Homologous Antagonist-Killer Protein / Q000378:metabolism*
C494772:BAK1 protein, human; C091732:BCL2-associated athanogene 1 protein; C107489:BIRC5 protein, human; D004268:DNA-Binding Proteins; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin; D014157:Transcription Factors; D050998:bcl-2 Homologous Antagonist-Killer Protein